Discover
Tremfya (guselkumab) / J&JJanssen brings to Spain Tremfya One-Press for the treatment of psoriasis [Google Translation] (Redacción Médica) - Oct 22, 2019 - "Janssen Pharmaceutical Companies of Johnson & Johnson has announced the commercialization in Spain of the Tremfya One-Press pre-filled pen, a new self-injectable administration device for guselkumab, indicated for the treatment of moderate to severe plaque psoriasis in adult candidates for systemic treatment....Designed to facilitate the time of the self-injection of patients with psoriasis."Tremfya (guselkumab) / J&JJanssen seeks to expand use of Tremfya (guselkumab) in the treatment of adults with active psoriatic arthritis (Businesswire) - Oct 23, 2019 - "The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Type II Variation Application to the European Medicines Agency (EMA) seeking first-in-class approval of TREMFYA (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA)."Cosentyx (secukinumab) / NovartisNovartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US (GlobeNewswire) - Oct 22, 2019 - "Continuing operations net sales up 13% (cc1, +10% USD) driven by: Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regions...Cosentyx met primary endpoints in nr-axSpA...FDA submission planned for Q4."Taltz (ixekizumab) / Eli LillyLilly presents positive results for Taltz (ixekizumab) in pediatric patients with moderate to severe plaque psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire) - Oct 28, 2019 - P3, N=201; "Eli Lilly and Company announced that TALTZ met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis...Results of the study were presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain. Based on these positive results, Lilly plans to submit for U.S. regulatory approval for pediatric patients with moderate to severe plaque psoriasis."mirikizumab (LY3074828) / Eli LillyMirikizumab: Primary completion of P3 VIVID-1 trial (NCT03926130) for Crohn’s disease in Feb 2022 (Eli Lilly) - Oct 23, 2019 - Q3 2019 Results: Completion of P3 VIVID-1 trial for Crohn’s disease in Jul 2023; Completion of P3 OASIS-1 trial (NCT03482011) in moderate-to-severe plaque psoriasis in Feb 2020 [Screenshot]mirikizumab (LY3074828) / Eli LillyMirikizumab: Primary completion of P3 OASIS-2 trial (NCT03535194) in moderate-to-severe plaque psoriasis in Mar 2020 (Eli Lilly) - Oct 23, 2019 - Q3 2019 Results: Completion of P3 OASIS-2 trial in moderate-to-severe plaque psoriasis in Dec 2020; Primary completion and completion of P3 OASIS-3 trial (NCT03556202) in moderate-to-severe plaque psoriasis in May 2024 [Screenshot]GSK2831781 / GSKGSK2831781 clinical trial estimate: Primary completion of P1 trial for healthy volunteers in Japan in January 2020 (GlobalData) - Oct 21, 2019 - A subscription to Thomson ONE is required to gain full access to report 67598395; Page no: 176; REPORT TITLE: "Immutep Ltd (IMM) - Financial analysis review”; AUTHOR: Globaldata; DATE: 09/24/2019Cosentyx (secukinumab) / NovartisCosentyx: Completion of P3b trial (NCT03504852) for psoriasis in H2 2020 (Novartis) - Oct 22, 2019 - Q3 2019 Results: Completion of P3 MATURE trial (NCT03589885) for psoriasis in H2 2020 [Screenshot]Cosentyx (secukinumab) / NovartisCosentyx: Completion of P3 trial (NCT02471144) for psoriasis in 2023 (Novartis) - Oct 22, 2019 - Q3 2019 Results: Completion of P3 trial (NCT03668613) for psoriasis in 2023 [Screenshot]Cosentyx (secukinumab) / NovartisCosentyx: Completion of P3 trial (NCT03031782) for psoriatic arthritis in 2021 (Novartis) - Oct 22, 2019 - Q3 2019 Results [Screenshot]
